←
Alan Bonder760 posts
Alan Bonder avatar

Alan Bonder

@BonderAlan

BIDMC Gastroenterology/Hepatology

◷ Joined October 2011▧ 88 Photos and videos
Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

7/8 The caveat: normal ALP is a surrogate. These trials are 12 months and small, and do not show fewer events yet. As the Hepatology editorial puts it: progress toward a goal, no evidence yet of arrival.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

6/8 Reading them together: endpoints differ slightly (IDEAL required a ≥15% drop on top of normal ALP), so avoid cross-trial comparisons. The message is the same: in this range, PPAR agonists normalize ALP in most patients.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

5/8 ELSPIRE: ALP normalization at week 52 in 85.3% with elafibranor vs 23.3% with placebo (p<0.0001). Mean ALP change −36.5% vs −4.2%. More patients reached complete biochemical response. No new safety signals.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

4/8 IDEAL: ALP normalization (≤ULN plus ≥15% drop) in 75.4% with seladelpar vs 16.1% with placebo (p<0.0001). ALP fell from month 1; mean change at 12 mo −33.8% vs −5.4%. Serious AEs 3.1% vs 12.9%.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

3/8 Shared design: patients on UDCA (or intolerant) with ALP >1 to <1.67×ULN, randomized 2:1 vs placebo, double-blind, 12 months. • IDEAL: seladelpar 10 mg, n=96 • ELSPIRE: elafibranor 80 mg, n=92

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

2/8 Why it matters: ALP above the ULN, even below 1.67×, is linked to disease progression and lower transplant-free survival. Normal ALP tracks better complication-free survival. Both trials target exactly this group.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 17

1/8 Is ALP <1.67×ULN good enough in #PBC? Two phase III trials published the same week say we can aim higher: IDEAL (seladelpar) and ELSPIRE (elafibranor) tested ALP normalization in so-called adequate responders 🧵

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

8/ What we still don't know: PPAR agonists and hard outcomes, how often to repeat elastography, and what to do after second-line failure. Congrats to the panel. Full guideline in Gastroenterology and Hepatology: gastrojournal.org/article/S0…

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

7/ After transplant for PBC: start UDCA as soon as possible to prevent recurrence and graft loss. Very low certainty, but cheap and safe.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

6/ Itch: linerixibat for moderate to severe cholestatic pruritus. The average benefit is modest (~0.8 points on WI-NRS vs placebo) and diarrhea is common, so this is a shared decision. Itch severity is defined by the patient, not by us.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

5/ Second line: PPAR agonists (elafibranor or seladelpar) as add-on to UDCA for inadequate response, or as monotherapy if UDCA is not tolerated. Low certainty, the data are biochemical. Outcome trials are ongoing.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

4/ Liver stiffness is now part of risk stratification. Check response to UDCA at 6–12 months, and at 6 months if high risk (LSM ≥10 kPa or age <62). Response = ALP + bilirubin, and ALP normalization is the ideal target.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

3/ UDCA 13–15 mg/kg/day for everyone at diagnosis. This is the only strong rec. Going above 15 mg/kg does not help. Keep it going even if ALP stays up, a partial response still has a survival benefit.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

2/ AMA negative but you suspect PBC? Check sp100 and gp210 before you go to biopsy. Very specific (sp100 ~96%) but not sensitive (~23%), so a negative test does not rule out PBC. Conditional rec, very low certainty.

Alan Bonder avatar
Alan Bonder@BonderAlan·Nov 10

1/ The first joint AGA/AASLD guideline on PBC is out, and it is focused on medication decisions. Very timely after OCA left the US market. 6 recommendations, only 1 strong. Here is what I think changes in clinic 🧵 #LiverTwitter #PBC